glp-1 obesity drug news today october 23 2025 Agonists Weight Loss Drugs Market Report, 2025-2030 The Obesity-Drug Revolution Is Stalling

McMaster University and Evidence Prime

Kaur P, Mahendru S, Mithal A

GLP1 Drugs (Wegovy, Zepbound): Pros: Highly effective, non-invasive, strong appetite suppression, rapid results

Whereas previous research has demonstrated the feasibility of using peptides to target nuclear hormone receptors 46,47 , to our knowledge, this is the first single molecule that uses a G-protein-coupled-receptor targeting approach to deliver a small-molecule modulator of an ionotropic receptor

DPP-4 regulates adipokines, as leptin and adiponectin, and a negative correlation between blood DPP-4 activity and circulating adiponectin levels in lean and obese subjects has been observed [48,49]